Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 01:58pm CET

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.


- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
04:15p SANOFI : gains two places in the Access to Medicine Index
12/01 MYMETICS : NetworkNewsBreaks – Mymetics (MYMX) Shares Skyrocket on Agreeme..
12/01 SANOFI : Receives FDA Approval of Soliqua 100/33 for the Treatment of Adults wit..
12/01 MYMETICS CORPORATION (OTCMKTS : MYMX) Files An 8-K Entry into a Material Definit..
11/29 NOVO NORDISK A/S : reports Tresiba insulin achieves target in study
11/29 SANOFI : to expand its Miskolc plant with an investment of 5 billion forints
11/29 SANOFI : FDA approval for Sanofi's Soliqua to treat type 2 Diabetes
11/28 SANOFI : Disclosure of trading in own shares
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/27DJDrugmakers Find Competition Doesn't Keep a Lid on Prices
More news
Sector news : Pharmaceuticals - NEC
12:36a Pharma execs weigh in on possible changes under Trump
12:24aDJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
12/01 GLAXOSMITHKLINE : GSK biotech asthma drug wins UK approval after extra price cut
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:48a Approvals Of Novel Molecules Set To Plunge In 2016
08:26a MyoKardia earns $25M milestone from Sanofi for MYK-491 IND
12/01 ALLERGAN : Low Enough To Like, Or Valeant-Lite?
11/30 Latest Setback Sends Amicus Back To The Drawing Board
11/30 Warren Buffett's Only 3 Dividend Stocks With 4%+ Yields
Financials (€)
Sales 2016 36 745 M
EBIT 2016 9 372 M
Net income 2016 5 436 M
Debt 2016 5 746 M
Yield 2016 4,00%
P/E ratio 2016 16,43
P/E ratio 2017 14,93
EV / Sales 2016 2,79x
EV / Sales 2017 2,82x
Capitalization 96 914 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,1 €
Spread / Average Target 7,9%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.38%103 497
JOHNSON & JOHNSON8.43%303 013
PFIZER INC.-2.54%190 910
ROCHE HOLDING LTD.-17.98%189 262
NOVARTIS AG-19.07%177 818
MERCK & CO., INC.15.85%167 524
More Results